Dataset Information

Institutional environments and breakthroughs in science. Comparison of France, Germany, the United Kingdom, and the United States.

ABSTRACT: Scientific and/or technical breakthroughs require the exploration of novel ideas and technologies. Yet, it has not been studied quantitatively how national institutional contexts either facilitate or stifle organizational support for exploration. Available qualitative evidence suggests that institutional contexts that exert weak control over universities and research organizations strengthen their capabilities to achieve scientific breakthroughs, while contexts with strong control constrain them. The paper is based on an analysis of the population of Nobel laureates in Physics, Chemistry and Physiology or Medicine. We examine to what extent existing qualitative findings for the biomedical sciences, which are partly based on Nobel laureates in Physiology or Medicine, can be substantiated both quantitatively and across the three Nobel Prize fields of science. We find that for most of the 20th century and the early 21st century, countries with weak institutional control (United Kingdom, United States) have outperformed those exerting strong control (France, Germany). These results are further corroborated when controlled by population sizes and by GDP per capita. In addition, these results hold not only for the biomedical sciences, but also for Physics and Chemistry. Furthermore, countries with weak institutional control have attracted many future Nobel laureates from countries with strong environments. In this regard, the United States appears to be a particularly attractive setting for conducting innovative research, and thus has been a magnet for young and promising scientists. However, future laureates working in institutional environments exerting weak control are not faster in accomplishing their prize-winning work compared to those laureates working in more restrictive institutional settings.

SUBMITTER: Heinze T

PROVIDER: S-EPMC7526927 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Institutional environments and breakthroughs in science. Comparison of France, Germany, the United Kingdom, and the United States.

Heinze Thomas T von der Heyden Marie M Pithan David D

PloS one 20200930 9

Scientific and/or technical breakthroughs require the exploration of novel ideas and technologies. Yet, it has not been studied quantitatively how national institutional contexts either facilitate or stifle organizational support for exploration. Available qualitative evidence suggests that institutional contexts that exert weak control over universities and research organizations strengthen their capabilities to achieve scientific breakthroughs, while contexts with strong control constrain them ...[more]

PMID: 32997679

Similar Datasets

Project description:IntroductionNewer treatment options for relapsed/refractory multiple myeloma (RRMM) with efficacy and safety profiles that differ from traditional therapies have facilitated personalized management strategies to optimize patient outcomes. In the context of such personalized management, understanding how treatment characteristics influence patients' preferences is essential. This study assessed patients' preferences for RRMM treatment attributes and determined trade-offs between potential benefits, administration procedures, and adverse effects.MethodsPatients' preferences were evaluated using a discrete choice experiment (DCE). Patients with RRMM who reported failing two lines of anti-myeloma treatment (immunomodulatory agent and a proteasome inhibitor [PI]) or ≥ 3 lines (including ≥1 PI, immunomodulatory agent, or anti-CD38 monoclonal antibody), were recruited across the US, UK, Italy, Germany, France, and Spain. DCE attributes and levels were identified using a targeted literature review, a review of clinical data for relevant RRMM treatments, qualitative patient interviews, and input from clinical and myeloma patient experts. The DCE was administered within an online survey from February-June 2022. Preference data were analyzed using an error-component logit model and willingness to make trade-offs for potential benefits, and relative attribute importance scores were calculated.ResultsOverall, 296 patients from the US (n = 100), UK (n = 49), Italy (n = 45), Germany (n = 43), France (n = 39), and Spain (n = 20) participated in the DCE. Mean (standard deviation) age was 63.8 (8.0) years, 84% had a caregiver, and patients had a median of 3 (range: 2-8) prior lines of therapy. Efficacy attributes most influenced patients' preferences, with increasing overall response rate (25-85%) and overall survival (6 months to 2 years) contributing to ~50% of treatment decision-making. Administration procedures were also considered important to patients. Avoiding individual side effects was considered relatively less important, with patients willing to tolerate increases in side effects for gains in efficacy. Patient characteristics such as rate of disease progression, sociodemographics, or clinical characteristics also influenced treatment preferences.ConclusionPatients with RRMM were willing to tolerate increased risk of side effects for higher efficacy. Preferences and risk tolerance varied between patients, with preference patterns differing by certain patient characteristics. This highlights the importance of shared decision-making for optimal treatment selection and patient outcomes.

Dataset Information

Institutional environments and breakthroughs in science. Comparison of France, Germany, the United Kingdom, and the United States.

Publications

Institutional environments and breakthroughs in science. Comparison of France, Germany, the United Kingdom, and the United States.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets